Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846

Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846

Background: There is no standard treatment for stage IV soft tissue sarcoma (STS) after the failure of Adriamycin-based chemotherapy. This phase II study (NCT03121846) assessed the efficacy and safety of apatinib (YN968D1), a new tyrosine kinase inhibitor that targets VEGFR-2, for patients with stag...

Full description

Bibliographic Details
Main Authors: Xinyue Liu, Jin Xu, Feng Li, Zhichao Liao, Zhiwu Ren, Lei Zhu, Yehui Shi, Gang Zhao, Xu Bai, Jun Zhao, Ruwei Xing, Sheng Teng, Yun Yang, Jilong Yang
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Soft tissue sarcoma
Apatinib
Efficacy
Progression-free survival
Toxicity
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332219352096

Internet

http://www.sciencedirect.com/science/article/pii/S0753332219352096

Similar Items